Drugs / Vorbipiprant
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05205330 | Nov 2021 → Dec 2026 expected | colorectal cancer, gastric cancer | Rottapharm Biotech | Active not recruiting | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT05845450 | May 2023 → May 2026 overdue | colorectal carcinoma | Gruppo Oncologico del Nord-Ovest | Recruiting | No outcome recorded |
| Phase 2 | NCT03163966 | Oct 2017 → Jan 2019 | — | Rottapharm Biotech | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | vorbipiprant | “CR6086 (Vorbipiprant) is a potent and selective, orally bioavailable, targeted immunomodulator small molecule acting as an EP4 receptor antagonist.” NCT05205330 ↗ |
| Known as | CR6086 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205330 ↗ |
| Known as | CR6086 SODIUM SALT | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067994 ↗ |
| Known as | VORBIPIPRANT SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL6067994 ↗ |
| Action | Inhibit | “Prostanoid EP4 receptor antagonist” CHEMBL6067994 ↗1“EP4 receptor antagonist” NCT03163966 ↗ |
| Modality | Small molecule | “small molecule prostaglandin EP4 receptor antagonist” NCT03163966 ↗ |
| Route | Oral | “oral CR6086 capsules” NCT03163966 ↗ |
| Target | PTGER4 | “Prostanoid EP4 receptor antagonist” CHEMBL6067994 ↗ |